Skip to content
Recall Observatory FDA recall evidence

Device product

Leccurate SARS-CoV-2, Antibody Rapid Test Kit (Colloidal Gold Immunochromatography), 1 test, IVD. for qualitative detection of IgM and/or IgG antibodies to SARS-CoV-2 in human serum, plasma and venipuncture whole blood for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Z-1619-2021

April 26, 2021

Class I

Product summary

Firm
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD
Event
Event 87737
Status
Completed
Classification
Class I
Quantity
8, 419, 545 units in total
Official record key
device-enforcement:Z-1619-2021

Official wording

Reason: Leccurate SARS-CoV-2, Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) is not authorized, cleared, or approved for marketing and/or distribution in the U.S.

Code information: All Lots distributed within the U.S.

Distribution pattern: Worldwide Distribution: US Distribution to states of: FL, IL, NY, GA, Puerto Rico and OUS countries of: Canada, Honduras, Peru, Dominican, Bolivia, Colombia, Mexico, Brazil, Argentina, Guatemala, Venezuela, Ecuador, Chile, Paraguay, Panama, Costa Rica, Peru and Hong Kong.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    Leccurate SARS-CoV-2, Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) is not authorized, cleared, or approved for marketing and/or distribution in the U.S.